Thymosin α1 continues to show promise as an enhancer for vaccine response

Annals of the New York Academy of Sciences

Volumn 1270, Issue 1, 2012, Pages 21-27

  Tuthill, Cynthia ^a   Rios, Israel ^a   De Rosa, Alfonso ^b   Camerini, Roberto ^b  

^a SciClone Pharmaceuticals Inc   (United States)

^b Sigma Tau SpA   (Italy)

Author keywords

Influenza; Thymalfasin; Thymosin; Vaccine; Zadaxin

Indexed keywords

HEPATITIS B VACCINE; INTERLEUKIN 2; THYMOSIN ALPHA1; VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; CHRONIC KIDNEY FAILURE; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; HEMAGGLUTINATION INHIBITION; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; INNATE IMMUNITY; NEGATIVE FEEDBACK; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; THYMUS FUNCTION; TREATMENT RESPONSE; VACCINATION;

EID: 84867380502     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06680.x     Document Type: Article

References (47)

1. Romani, L., F. Bistoni, R. Gaziano, et al. 2004. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232-4239.
2. Romani L., F. Bistoni, K. Perruccio, et al. 2006. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265-2274.
3. Peng, Y., Z. Chen, W. Yu, et al. 2008. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol. Int. 32: 1265-1271.
4. Yao, Q., L.X. Doan, R. Zhang, et al. 2007. Thymosin-a1 modulated dendritic cell differentiation and functional maturation from peripheral blood CD14+ monocytes. Immunol. Lett. 110: 110-120.
5. Gramenzi, A., C. Cursaro, M. Margotti, et al. 2008. In vitro effect of thymosin alpha 1 and interferon alpha on Th1 and Th2 cytokine synthesis in patients with HBEAg-negative chronic hepatitis B. J. Viral Hepatitis 15: 442-448.
6. Cursaro, C., M. Margotti, L. Favarelli, et al. 1998. Thymosinα1 (Tα1) plus interferonα (IFNα) enhance the immune and antiviral response of patients with hepatitis C virus infection. Hepatology 28: 361A.
7. Serrate, S., R. Schulof, L. Leondaridis, et al. 1987. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J. Immunol. 139: 2338-2343.
8. Sztein, M., S. Serrate & A. Goldstein. 1986. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl. Acad. Sci. USA 83: 6107-6111.
9. Sztein, M. & S. Serrate. 1989. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int. J. Immunopharmacol. 11: 789-800.
10. Leichtling, K.D., S.A. Serrate & M.B. Sztein. 1990. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int. J. Immunopharmacol. 12: 19-29.
11. Svedersky, L., A. Hui, L. May, et al. 1982. Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by Na-desacetylthymosin alpha 1. Eur. J. Immunol. 12: 244-247.
12. Hsia, J., N. Sarin, J.H. Oliver & A.L. Goldstein. 1989. Aspirin and thymosin increase interleukin-2 and interferon-gamma production by human peripheral blood lymphocytes. Immunopharmacology 17: 167-173.
13. Mutchnick, M.G., H.D. Appelman, H.T. Chung, et al. 1991. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 14: 409-415.
14. Ershler, W., J. Hebert, A. Blow, et al. 1985. Effect of thymosin alpha one on specific antibody response and susceptibility to infection in young and aged mice. Int. J. Immunopharmacol. 7: 465-471.
15. Effros, R.B., A. Casillas & R.L. Walford. 1988. The effect of thymosin alpha 1 on immunity to influenza in aged mice. In Aging: Immunology and Infectious Disease. Vol. 1. 31-40. Mary Ann Liebert, Inc. New York, NY.
16. Di Francesco, P., F. Pica, S. Marini, et al. 1992. Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration. Int. J. Immunopharmacol. 14: 1-9.
17. Ershler, W., A. Moore & M. Socinski. 1984. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J. Clin. Immunol. 4: 445-454.
18. Ciancio, A., P. Andreone, S. Kaiser, et al. 2012. Thymosin alpha 1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J. Viral Hepat. 19(Suppl. 1): 52-59.
19. Zhang, P., J. Chan, A.M. Dragoi, et al. 2005. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep. 6: 531-537.
20. Arrighi, J.F., M. Rebsamen, F. Rousset, et al. 2001. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysacharide, TNF-q, and contact sensitizers. J. Immunol. 166: 3837-3845.
21. Iijima, N., Y. Yanagawa & K. Onoe. 2003. Role of early- or late-phase activation of p38 mitogen-activated protein kinase induced by tumor necrosis factor-a or 2, 4-dinitrochlorobenzene during maturation of murine dendritic cells. Immunology 110: 322-328.
22. Yoshimura, S., J. Bondeson, F.M. Brennan, et al. 2001. Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with proteasome inhibitor PSI. Eur. J. Immunol. 31: 1883-1893.
23. Knutsen, A.P., J.J. Freeman, K.R. Mueller, et al. 1999. Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3 + 4+ cells in an in vitro thymic epithelia organ coculture model. Int. J. Immunopharmacol. 21: 15-26.
24. Pierliugi, B., C. D'Angelo, F. Fallarino, et al. 2010. Thymosin alpha 1: the regulator of regulators? Ann. N.Y. Acad. Sci. 1194: 1-5.
25. Shrivastava, P., S.M. Singh & N. Singh. 2004. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells. J. Biomed. Sci. 11: 623-630.
26. Shen, S., J. Josselson, C. McRoy, et al. 1987. Effect of thymosin alpha 1 on heptavax-B vaccination among hemodialysis patients. Kidney Int. 31: 217.
27. Schulof, R.S., M.J. Lloyd, P.A. Cleary, et al. 1985. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin alpha 1 in patients with lung cancer. J. Biol. Response Modifiers 4: 147-158.
28. Stefanini, G.F., F.G. Foschi, E. Castelli, et al. 1998. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 45: 209-215.
29. de Weck, A., F. Kristensen, F. Joncourt, et al. 1984. Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions. Springer Semin. Immunopathol. 7: 273-289.
30. Makinodan, T. & W. Peterson. 1962. Relative antibody-forming capacity of spleen cells as a function ofage. Proc. Natl. Acad. Sci. USA 48: 234-238.
31. Wade, A.W. & M.R. Szewczuk. 1984. Aging, idiotype repertoire shifts, and compartmentalization of the mucosal-associated lymphoid system. Adv. Immunol. 36: 143-188.
32. Ershler, W., A. Moore, M. Hacker, et al. 1984. Specific antibody synthesis in vitro. II. Age-associated thymosin enhancement of antitetanus antibody synthesis. Immunopharmacology 8: 69-77.
33. Bramwell, S.P., D.J. Tsakiris, J.D. Briggs, et al. 1985. Dinitrochlorobenzene skin testing predicts response to hepatitis B vaccine in dialysis patients. Lancet 1: 1412-1415.
34. Dammin, G., N. Couch & J. Murray. 1957. Prolonged survival of skin homografts in uremic patients. Paper presented at: Second Tissue Homotransplantation Conference. New York, NY.
35. Lawrence, H.S. 1965. Uremia: nature's immunosuppressive device [editorial]. Ann. Intern. Med. 62: 166-170.
36. Revie, D., S. Shen, J. Ordonez, et al. 1985. T-cell subsets and status of hepatitis B surface antigen and antibody in end-stage renal disease patients. Kidney Int. 27: 150.
37. Sanders, C.V., Jr., L.P. Luby, J.P. Sanford & A.R. Hull. 1971. Suppression of interferon response in lymphocytes from patients with uremia. J. Lab. Clin. Med. 77: 768-776.
38. Stevens, C.E., H.J. Alter, P.E. Taylor, et al. 1984. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N. Engl. J. Med. 311: 496-501.
39. Grob, P., U. Binswanger, K. Zaruba, et al. 1983. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res. 3: 43-52.
40. Crosnier, J., P. Jungers, A.M. Courouc, et al. 1981. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, medical staff. Lancet 1: 455-459.
41. Gravenstein, S., W.B. Ershler, S. Drumaskin, et al. 1986. Anti-influenza antibody response: augmentation in elderly -non-responders by thymosin alpha 1. The Gerontologist 26: 150A.
42. Gravenstein, S., E.H. Duthie, B.A. Miller, et al. 1989. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J. Am. Geriatr. Soc. 37: 1-8.
43. McConnell, L., S. Gravenstein, E. Roecker, et al. 1989. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1. The Gerentologist 29: 188A.
44. Shen, S.Y., Q.B. Corteza, J. Josselson, et al. 1990. Age-dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In Biomedical Advances in Aging. A.L. Goldstein, Ed.: 523-530. Plenum Press. New York, NY.
45. Shen, S., J. Josselson, C. McRoy, et al. 1987. Effects of thymosin alpha 1 on peripheral T-cell and Heptavax-B vaccination in previously non-responsive hemodialysis patients. Hepatology 7: 1120.
46. Tuthill, C., A. DeRosa, R. Camerini, et al. 2010. The immunomodulatory peptide thymosin alpha 1 enhances response to influenza vaccine. National Foundation for Infectious Diseases 13th Annual Meeting. Bethesda, MD.
47. Carraro, G., A. Naso, E. Montomoli, et al. 2012. Thymosin alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine 30: 1170-1180.